Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

QURE vs TLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

TLX Overall Winner 6-Pillar Tally: QURE 2 – 4 TLX Matrix Metrics: QURE 4 – 6 TLX

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over uniQure N.V. (QURE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). QURE carries a Unified Composite Score of 48.9/100 (HOLD) at $22.10 (27.9x Forward P/E, -994.0% operating margin), whereas TLX carries 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin).

  • Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.2% vs. -994.0% operating margin) and revenue trajectory (+22.3% vs. +40.4% YoY).
  • Technical & Structure Timing Caution: QURE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About QURE vs TLX
QURE NASDAQ
uniQure N.V.
Pharmaceutical Preparations
$22.10
-7.18% 1D
Market Cap $1.7B
TTM Revenue $20M
Forward P/E 27.9x
Beta / 30D Vol 0.81β · 81% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 42.0 Fund 55.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -25.1%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $23.25 · SMA50: $29.05
TLX NASDAQ Head-to-Head Winner
Telix Pharmaceuticals Limited American Depositary Shares
Pharmaceutical Preparations
$8.96
-2.98% 1D
Market Cap $3.2B
TTM Revenue $891M
Forward P/E N/M
Beta / 30D Vol 0.84β · 62% Vol
Unified Composite Score
46.4 / 100 HOLD
Tech 64.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.7%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $9.46 · SMA50: $10.61

6-Pillar Scorecard Institutional Category Breakdown (QURE 2 – 4 TLX)

Columns: Metric · QURE · TLX
1. Valuation Multiples QURE
Forward P/E 27.9x N/M
Trailing P/E 27.9x 93.6x
PEG Ratio N/M N/M
EV / Revenue 83.9x 3.6x
2. Growth & Scale TLX
Revenue Growth (YoY) +40.4% +22.3%
Earnings Growth (YoY) -18.2% +0.0%
TTM Revenue (USD) $20M $891M
Market Cap $1.7B $3.2B
3. Profitability & Quality TLX
Gross Margin N/A 47.6%
Operating Margin -994.0% 6.2%
Net Profit Margin 0.0% 3.8%
Return on Equity (ROE) -89.0% 7.4%
4. Balance Sheet & Cash Flow TLX
Cash Generation (TTM) -$193M $70M EBITDA
Cash Flow Margin N/A 7.8% EBITDA Mgn
Net Cash / Leverage $36M Net Cash $1.44 Book/Sh · 7.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning QURE
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 56.2% (<1st %ile) N/A (N/A)
Put/Call OI Skew 0.14x (Call-Skewed) Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TLX
OpEx & R&D Intensity N/A 41.4% of Rev ($369M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: QURE (4) vs TLX (6)
Institutional Metric QURE TLX Criterion Row Edge
Market Capitalization
Scale
$1.7B $3.2B Larger Scale TLX
Trailing P/E Ratio
Valuation
27.9x 93.6x Lower Multiple QURE
Forward P/E Ratio
Valuation
27.9x N/M Lower Multiple QURE
Revenue Growth (YoY)
Growth
+40.4% +22.3% Higher Growth QURE
Operating Margin (TTM)
Profitability
-994.0% 6.2% Higher Margin TLX
Net Profit Margin
Profitability
0.0% 3.8% Higher Margin TLX
Return on Equity (ROE)
Capital Efficiency
-89.0% 7.4% Higher ROE TLX
52-Week Range Position
Momentum
31% ($9–$52) 39% ($6–$13) Stronger Trend TLX
Beta / 30D Volatility
Risk Regime
0.81β · 81% Vol 0.84β · 62% Vol Lower Realized Risk TLX
Unified Institutional Score
Composite Signal
48.9 / 100 (HOLD) 46.4 / 100 (HOLD) Higher Composite QURE
Trailing 12M Revenue (USD)
Operating Scale
$20M $891M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 47.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 83.9x EV/Rev N/M PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$193M ($36M Net Cash) $70M EBITDA ($1.44 Book/Sh · 7.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon QURE +17.7 pp
QURE: +1.47% · TLX: -16.23%
3M Horizon TLX +28.74 pp
QURE: -53.36% · TLX: -24.62%
6M Horizon QURE +1.54 pp
QURE: -11.35% · TLX: -12.89%
1Y Horizon TLX +21.32 pp
QURE: -27.16% · TLX: -5.84%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on QURE vs TLX. Trailing 12-month operating profitability (QURE -994.0% vs TLX 6.2%) and valuation multiples (QURE 27.9x vs TLX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

QURE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$20M
Gross MarginN/A
Op. Margin-994.0%
ROE / Fwd P/E-89.0% · 27.9x
TLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$891M
Gross Margin47.6%
Op. Margin6.2%
ROE / Fwd P/E7.4% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
QURE BREAKDOWN
102d in phase · OBV NEUTRAL
Current IV 56.2%
IV Percentile <1st %ile
Put/Call OI Skew 0.14x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact QURE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
QURE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -994.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TLX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.2B market capitalization and 6.2% operating margin.
OpEx & R&D Reinvestment 41.4% of Rev ($369M)
90D Engineering Disclosures 0 Published

Investor FAQ QURE vs TLX Key Questions & Quantitative Answers

As of Nov 16, 2026, Telix Pharmaceuticals Limited (TLX) is the stronger overall head-to-head candidate over uniQure N.V. (QURE) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). QURE carries a Unified Composite Score of 48.9/100 (HOLD) at $22.10 (27.9x Forward P/E, -994.0% operating margin), whereas TLX carries 46.4/100 (HOLD) at $8.96 (N/M Forward P/E, 6.2% operating margin). Composite vs. Pillar Nuance: While QURE currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. TLX 46.4/100 HOLD), TLX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (6.2% vs. -994.0% operating margin) and revenue trajectory (+22.3% vs. +40.4% YoY). Technical & Structure Timing Caution: QURE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.9); meanwhile TLX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TLX leads the Growth & Scale pillar: QURE posts +40.4% YoY revenue growth and -18.2% YoY earnings growth on $20M TTM revenue (N/A gross margin, -994.0% operating margin), compared with TLX at +22.3% YoY revenue growth and +0.0% YoY earnings growth on $891M TTM revenue (47.6% gross margin, 6.2% operating margin). On trailing 12-month operating scale, QURE generates $20M in USD-normalized revenue versus $891M for TLX. In operating R&D and SG&A reinvestment, QURE deploys N/A (0 90-day corporate R&D disclosures) versus 41.4% of Rev ($369M) (0 disclosures) for TLX.

QURE screens cheaper on headline valuation multiples. QURE trades at 27.9x Forward P/E, 27.9x Trailing P/E, N/M PEG, and 83.9x EV/Revenue (unreported FCF margin), whereas TLX trades at N/M Forward P/E, 93.6x Trailing P/E, N/M PEG, and 3.6x EV/Revenue (7.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against QURE (-89.0% ROE) versus TLX (7.4% ROE) capital efficiency.

In options market volatility and institutional positioning, QURE carries 56.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.81β · 81% Vol realized risk). By comparison, TLX carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.84β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.